Joseph Menczer

Summary

Affiliation: Bnai Zion Medical Center
Country: Israel

Publications

  1. pmc Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
    J Gynecol Oncol 22:183-7. 2011
  2. ncbi request reprint The effect of coexisting uterine myomas on clinico-pathological variables of endometrial carcinoma
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center Holon, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
    Eur J Gynaecol Oncol 34:545-7. 2013
  3. ncbi request reprint Patient-tailored conservative surgical treatment of invasive uterine cervical squamous cell carcinoma. A review
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Minerva Ginecol 65:407-15. 2013
  4. ncbi request reprint Conservative fertility-sparing surgical treatment of invasive epithelial ovarian cancer: when is it acceptable?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    Isr Med Assoc J 15:116-20. 2013
  5. doi request reprint The effect of hysterectomy on survival of patients with borderline ovarian tumors
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 125:372-5. 2012
  6. doi request reprint Risk factor proportions in Israeli patients with cervical intraepithelial neoplasia 3 and invasive squamous cell carcinoma
    Joseph Menczer
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    J Low Genit Tract Dis 12:220-3. 2008
  7. doi request reprint The effect of symptom duration in epithelial ovarian cancer on prognostic factors
    Joseph Menczer
    Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Arch Gynecol Obstet 279:797-801. 2009
  8. doi request reprint Incidence trends of cervical adenocarcinoma in Israeli Jewish women. A population-based study
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel
    Acta Obstet Gynecol Scand 88:280-5. 2009
  9. doi request reprint Cox-2 expression in ovarian malignancies: a review of the clinical aspects
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Eur J Obstet Gynecol Reprod Biol 146:129-32. 2009
  10. ncbi request reprint Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Eur J Gynaecol Oncol 30:375-8. 2009

Detail Information

Publications40

  1. pmc Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
    J Gynecol Oncol 22:183-7. 2011
    ..To assess whether there is an association between improvement of computed tomography imaging results prior to interval debulking with survival in patients treated by neoadjuvant chemotherapy...
  2. ncbi request reprint The effect of coexisting uterine myomas on clinico-pathological variables of endometrial carcinoma
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center Holon, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
    Eur J Gynaecol Oncol 34:545-7. 2013
    ..To assess the prevalence of leiomyomas in patients with endometrial carcinoma (EC) and the association of their presence with clinico-pathological variables and with survival...
  3. ncbi request reprint Patient-tailored conservative surgical treatment of invasive uterine cervical squamous cell carcinoma. A review
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Minerva Ginecol 65:407-15. 2013
    ..A more conservative, patient-tailored surgical approach in selected cases of early SCC is possible resulting in lower morbidity and preservation of fertility without compromising the outcome. ..
  4. ncbi request reprint Conservative fertility-sparing surgical treatment of invasive epithelial ovarian cancer: when is it acceptable?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    Isr Med Assoc J 15:116-20. 2013
    ..Although favorable results have been reported in many studies that included conservatively treated patients with higher stage and grade, their number is too small to draw any conclusion...
  5. doi request reprint The effect of hysterectomy on survival of patients with borderline ovarian tumors
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 125:372-5. 2012
    ..The purpose of the present study was to assess the frequency of uterine involvement in patients with BOTs and the effect of hysterectomy on survival...
  6. doi request reprint Risk factor proportions in Israeli patients with cervical intraepithelial neoplasia 3 and invasive squamous cell carcinoma
    Joseph Menczer
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    J Low Genit Tract Dis 12:220-3. 2008
    ....
  7. doi request reprint The effect of symptom duration in epithelial ovarian cancer on prognostic factors
    Joseph Menczer
    Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Arch Gynecol Obstet 279:797-801. 2009
    ..To assess the association between duration of symptoms and main prognostic factors of invasive epithelial ovarian cancer (EOC)...
  8. doi request reprint Incidence trends of cervical adenocarcinoma in Israeli Jewish women. A population-based study
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel
    Acta Obstet Gynecol Scand 88:280-5. 2009
    ..To assess the trend over time of the relative frequency and incidence of adenocarcinoma (AC) in Israeli Jewish women...
  9. doi request reprint Cox-2 expression in ovarian malignancies: a review of the clinical aspects
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Eur J Obstet Gynecol Reprod Biol 146:129-32. 2009
    ..Clinical studies dealing with the effect of COX-2 inhibitors on outcome are scarce. The use of COX-2 expression in gynecological malignancies in clinical practice remains to be elucidated...
  10. ncbi request reprint Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Eur J Gynaecol Oncol 30:375-8. 2009
    ....
  11. ncbi request reprint Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Eur J Gynaecol Oncol 30:531-5. 2009
    ..The aim of the study was to assess whether COX-2 expression in epithelial ovarian carcinoma (EOC) tissue can distinguish between platin-sensitive and platin-resistant tumors...
  12. doi request reprint COX-2 expression in uterine carcinosarcoma
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Acta Obstet Gynecol Scand 89:120-5. 2010
    ..To assess cyclooxygenase-2 (COX-2) expression in the carcinomatous and sarcomatous elements of uterine carcinosarcoma...
  13. doi request reprint Incidence rates of cervical carcinoma among first- and second-generation women of North African origin in Israel
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel
    Int J Gynecol Cancer 19:1606-9. 2009
    ..To evaluate the incidence rates of cervical cancer by ethnic origins and compare these rates between first- and second-generation women of North African origin...
  14. doi request reprint A population-based study of selected demographic characteristics of Israeli-Jewish women with cervical squamous cell carcinoma
    Joseph Menczer
    Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, E Wolfson Medical Center, Holon, Israel
    Arch Gynecol Obstet 283:629-33. 2011
    ..The aim of the present study was to assess selected demographic characteristics of Israeli-Jewish women with cervical squamous cell carcinoma (SCC) in an attempt to identify current selected risk factors...
  15. doi request reprint COX-2 expression in nonepithelial ovarian malignancies
    Joseph Menczer
    Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Int J Gynecol Pathol 30:41-5. 2011
    ..Positive staining was observed only in 1 immature teratoma and in none of the dysgerminomas.Our data seem to indicate that COX-2 expression by immunohistochemical methods is not frequent in nonepithelial ovarian malignancies...
  16. ncbi request reprint Cervical neoplasia in Israeli Jewish women: characteristics in a low risk population
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    Isr Med Assoc J 13:700-4. 2011
    ..In view of the similarities to other populations the reason for the low incidence in Israel remains obscure, and whether it can be attributed to genetic reasons or to some traditional habits is yet to be confirmed...
  17. ncbi request reprint The human papillomavirus vaccine and its relevance in Israel
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    Isr Med Assoc J 9:546-9. 2007
  18. ncbi request reprint Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 88:58-61. 2003
    ..The aim of the present study was to compare demographic and clinical characteristics of primary peritoneal carcinoma (PPC) to ovarian carcinoma (OvC) with regard to BRCA mutation frequencies...
  19. ncbi request reprint The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Wolfson Medical Center, Holon, Israel
    Isr Med Assoc J 5:120-3. 2003
  20. ncbi request reprint Expression of c-kit in uterine carcinosarcoma
    Joseph Menczer
    Department of Obstetrics and Gynecology, Gynecologic Oncology Unit, Edith Wolfson Medical Center, Holon 58100, Israel
    Gynecol Oncol 96:210-5. 2005
    ..The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous element of carcinosarcoma to identify if KIT represents a therapeutic target for treatment of this neoplasm...
  21. ncbi request reprint A comparison between different postoperative treatment modalities of uterine carcinosarcoma
    Joseph Menczer
    Departments of Obstetrics and Gynecology, Gynecologic Oncology Units, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 97:166-70. 2005
    ..e., chemotherapy followed by WPI) in the third...
  22. ncbi request reprint Primary peritoneal carcinoma--Uterine involvement and hysterectomy
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 100:565-9. 2006
    ..To assess the frequency of uterine involvement in primary peritoneal carcinoma (PPC) and to describe selected clinical characteristics in patients with and without hysterectomy...
  23. ncbi request reprint A decreasing incidence of ovarian carcinoma in Israel
    J Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel 58100
    Int J Gynecol Cancer 16:41-4. 2006
    ..55 in 2002. The decrease in incidence was evident in all ethnic groups except those born in Asia and in all the age groups older than 35 years. The decrease in incidence of ovarian carcinoma is gratifying, but its reason remains obscure...
  24. ncbi request reprint Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson, Medical Center, Holon, Israel
    Gynecol Oncol 103:137-40. 2006
    ..To assess the value of routine periodic physical examination in the follow-up of ovarian (OvC) and primary peritoneal carcinoma (PPC) patients with pretreatment elevated CA125 levels...
  25. ncbi request reprint Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 104:675-9. 2007
    ..The aim of the present study was to asses the ability of Her-2/neu immunohistochemical staining of the molar tissue to predict the risk of developing gestational trophoblastic neoplasia (GTN)...
  26. doi request reprint Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma
    Tamar Safra
    Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Gynecol Oncol 114:215-8. 2009
    ..To evaluate safety and outcome of weekly carboplatin and paclitaxel as the initial postoperative adjuvant chemotherapy for epithelial ovarian carcinoma (EOC) patients...
  27. ncbi request reprint Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response
    Tally Levy
    Division of Gynecologic Oncology, Edith Wolfson Medical Center, Holon, Israel
    Int J Gynecol Cancer 22:1344-8. 2012
    ....
  28. ncbi request reprint Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients
    Tamar Safra
    Department of Medical Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Acta Oncol 45:463-8. 2006
    ..7%) and nausea and vomiting in two (4.7%). Single agent gemcitabine is an attractive option for heavily pretreated EOC patients. The significant difference between platinum-sensitive and resistant patients' warrants further investigation...
  29. ncbi request reprint Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study
    Giulia Barda
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Am J Obstet Gynecol 190:1039-45. 2004
    ..This study was undertaken to characterize primary peritoneal carcinoma (PPC) compared with ovarian carcinoma (OvC)...
  30. doi request reprint The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients
    Tally Levy
    Division of Gynecologic Oncology, E Wolfson Medical Center, Holon, Israel
    Gynecol Oncol 129:165-8. 2013
    ..We assessed whether the pattern of CA125 ascent to above the normal range at recurrence is associated with outcome...
  31. ncbi request reprint Is Her-2/neu expressed in nonepithelial ovarian malignancies?
    Joseph Menczer
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Am J Obstet Gynecol 196:79.e1-4. 2007
    ..The objective of this study was to assess the expression of Her-2/neu in nonepithelial ovarian malignancies...
  32. doi request reprint Selected demographic characteristics of Israeli Jewish women with high-grade cervical intraepithelial neoplasia (CIN3): a population-based study
    Liron Kogan
    Department of Obstetrics and Gynecology, The Hadassah Ein Kerem University Medical Center, Jerusalem, Israel
    Arch Gynecol Obstet 283:329-33. 2011
    ..The aim of the present study was to assess selected demographic characteristics of Israeli Jewish CIN3 patients in an attempt to identify the risk factors in this population...
  33. ncbi request reprint Selected clinical characteristics of Israeli Jewish women with squamous cell carcinoma of the uterine cervix: a population-based study
    Liron Kogan
    Department of Obstetrics and Gynecology, Hebrew University Hadassah Medical Center Ein Kerem Campus, Jerusalem, Israel
    Isr Med Assoc J 13:84-6. 2011
    ..The age-standardized incidence rate of invasive cervical cancer in Israeli Jewish women is persistently low. Selected demographic characteristics of Israeli Jewish women with cervical squamous cell carcinoma (SCC) were reported recently...
  34. ncbi request reprint Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer
    Tally Levy
    Division of Gynecologic Oncology, Wolfson Medical Center, Holon, The Sackler Faculty of Medicine, Tel Aviv, Israel
    Gynecol Oncol 95:686-90. 2004
    ..To assess the toxicity and effectiveness of once-weekly administration of topotecan (Hycamtin; GlaxoSmithKline) for relapsed ovarian and primary peritoneal cancer...
  35. ncbi request reprint Endometrial endometrioid carcinoma: a glimpse at the natural course
    Tally Levy
    Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E Wolfson Medical Center, Holon, Israel
    Am J Obstet Gynecol 195:454-7. 2006
    ..This study was undertaken to assess the natural course of endometrial endometrioid carcinoma by identifying untreated patients and those with a prolonged (>6 months) treatment delay...
  36. doi request reprint Is removal of asymptomatic cervical polyps necessary?: histologic findings in asymptomatic Israeli Jewish women
    Oran Goldshmid
    Maccabi Health Service clinics, Tel Aviv, Israel
    J Low Genit Tract Dis 15:259-62. 2011
    ..The purpose of the present study was to assess the frequency of abnormal histologic findings in polyps of asymptomatic Israeli Jewish women who are known to have a low incidence of cervical neoplasia...
  37. ncbi request reprint Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer
    Walter H Gotlieb
    Department of Gynecologic Oncology, Sheba Medical Center Tel Hashomer, Israel
    Gynecol Oncol 97:780-3. 2005
    ..Evaluation whether Jewish founder mutations in BRCA predispose to borderline tumors as they do to early invasive ovarian cancers...
  38. ncbi request reprint Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study
    Joni L Rutter
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7246, USA
    J Natl Cancer Inst 95:1072-8. 2003
    ..We assessed the level and persistence of reduction of ovarian (including peritoneal) cancer risk after gynecologic surgeries for women who carry BRCA1/2 mutations but were not selected from high-risk clinics...
  39. ncbi request reprint Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
    Tamar Safra
    Department of Oncology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv, Israel 64239
    Gynecol Oncol 105:205-10. 2007
    ..We assessed the efficacy and toxicity of once-weekly topotecan (Hycamtin; GlaxoSmithKline) for relapsed or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC)...
  40. ncbi request reprint Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation"
    Joseph Menczer
    Gynecol Oncol 96:906-7; author reply 907. 2005